"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 1: When to Suspect aHUS in Oncology Patients

Atypical hemolytic uremic syndrome (aHUS) in patients with malignancy or undergoing cancer-directed therapy is likely under-recognized, yet early identification can have a profound impact on patient outcomes.In this FLASCO OncoPod roundtable, Drs. Jaglal, Fu, and Shahzad examine the clinical realities of drug-induced and malignancy-associated aHUS, emphasizing the importance of maintaining a high index of suspicion in complex oncology cases. Through expert insight and real-world experience, they explore how subtle changes in laboratory values and clinical presentation can signal a more serious underlying process.In this first segment, the discussion centers on when to suspect aHUS in oncology patients, guided by an illustrative case that brings the diagnostic challenge into focus. The faculty highlight key warning signs, including evolving anemia, thrombocytopenia, and renal dysfunction, and underscore how timely recognition can significantly influence both renal recovery and overall patient trajectory.